Jane Osbourn

CSO Alchemab Therapeutics


Dr Jane K Osbourn OBE FMed Sci

Jane is Chief Scientific Officer at Alchemab Therapeutics, which focusses on identifying self-protectiveantibodies as therapies for neurodegeneration and oncology. She was an early employee of Cambridge Antibody Technology, which became MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of phage display technology, authored many key publications and patents and contributed to the discovery and development of eight marketed drugs. She is passionate aboutthe development of the biotechnology sector and served as Chair of the UK BioIndustry Association from 2015-2019. She is also the Chair of Mogrify, a Cambridge-based cell-therapy company, a Director of Cambridge Enterprise, and of Babraham Research Campus. In 2019 she was awarded an OBE for services to drug discovery, development and biotechnology, and the Scrip Lifetime Achievement Award for contribution to the pharma industry.

amazing people

Other Speakers

Gary Nabel

President and CEO of ModeX Therapeutics

Gestur Vidarsson

Professor, PI and head of Immunoglobulin Researchat Sanquin Researc at the Utrecht University

Jane Osbourn

CSO Alchemab Therapeutics

Bryan Briney

Professor in the department of Immunology and Microbiology at Scripps Research
Brandon Dekosky

Assistant Professor at MIT
See All Speakers